Please login to the form below

Not currently logged in
Email:
Password:

primary hyperoxaluria type 1

This page shows the latest primary hyperoxaluria type 1 news and features for those working in and with pharma, biotech and healthcare.

Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

Lumasiran hits its objectives in the 20-patient phase 3 trial, which involved patients aged six and over with primary hyperoxaluria type 1 (PH1), a life-threatening but ultra-rare condition ... type 2 form (PH2) of the disease, which is caused by a

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics